Phacilitate Leaders Forum

17th - 18th SEPTEMBER 2019



Suso Platero

Suso Platero

Executive Director, Covance

Key Roles and Responsibilities
Leads Biomarker Solution Center to provide clients
with biomarker consultation and strategy, bringing both
Covance and LabCorp laboratories resources to aid in the
development of biomarker delivery

Partners with medical and scientific leaders across
Covance and LabCorp business units to communicate
and collaborate on precision medicine solutions in the
areas of oncology, immuno-oncology, cardiovascular and
metabolics, neuroscience and immunology
Interacts with federal agencies and key opinion leaders in
oncology and immuno-oncology

Areas of Expertise
Translational Research in Oncology and
- Development of biomarker plans for oncology and
immuno-oncology studies including discovery and
application in clinical trials
- Alignment of biomarker plans with executable working

Strategy Development
- Partnering with commercial and marketing to increase
biomarker and laboratory sales
- Development of new initiatives in biomarkers, precision
medicine, oncology and immuno-oncology

Professional Highlights

20+ years of experience in contract research organizations,
diagnostic, pharmaceutical industries and academia

Contributed to the discovery of biomarkers, their
application in clinical trials and their development in
companion diagnostics

Before joining Covance, served as Senior Director,
Oncology Translational Research, Janssen Pharmaceutical
Companies of J&J; Associate Director, Clinical Biomarkers,
Bristol-Myers Squibb; and Senior Project Scientist, Becton

Developed a companion diagnostic for a drug that was
awarded breakthrough therapy by the FDA in 2018

Awards include Philip B. Hofmann Scientific
Research Award for outstanding achievement in R&D
and Innovation Leadership Award while at Janssen

  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd